Phase 3 trial of coronavir (favipiravir) in patients with mild to moderate COVID-19.
Т. А. Руженцова, Rodion A Oseshnyuk, Tatyana N Soluyanova, Elena Petrovna Dmitrikova, Dzhavanshir M Mustafaev, Konstantin A. Pokrovskiy, Tatyana N. Markova, Marina G Rusanova, N. E. Kostina, Alina S. Agafina, Yuri F Brook, Олег Бронов, Evgeny I Shults, O. V. Filon
Abstract
5.0 (IQR 4.5; 5.5) days in the SOC group (HR 2.11; 95% CI 1.04-4.31; P=0.038). The rate of viral elimination on Day 5 in the favipiravir group was significantly higher than in SOC group: 81.2% vs. 67.9% (RR 1.22; 05% CI 1.00-1.48; P=0.022). The rate of clinical improvement on Day 7 in the favipiravir group was 1.5-fold higher than in SOC group: 52.7% vs. 35.8% (RR 1.50; 95% CI 1.02-2.22; P=0.020). Favipiravir was well-tolerated and the most common adverse reactions were asymptomatic hyperuricemia, transient elevation of ALT & AST, and mild gastrointestinal disorders. Favipiravir was superior to the SOC in shortening the time to clinical improvement in patients with mild to moderate COVID-19.